BioPharma Resources

Drug Trial Radar · NCT01497002

Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a

Randomized Phase III Study Comparing the OSHO Arm to the Standard Intergroup Arm.

Last checked: Nov 19, 2026Latest source record: Jan 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,222 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,222

Actual

Start

Apr 2005

Primary completion

Jul 18, 2018

Study completion Jul 18, 2018

Sponsor

Lead sponsor
University of LeipzigAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 22, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Improvement of the treatment-results in elderly patients with acute myeloid leukemia through intensification of consolidation chemotherapy and/or allografting as consolidative immunotherapy

Conditions

  • Acute Myeloid Leukaemia

Interventions

  • CytarabineDrug

    Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.

  • human stem cellsBiological

    Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event free survivalTime frame: after 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Leipzig, Hematology

    Leipzig, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.